Affymax, Inc. is a biopharmaceutical company that focuses on developing novel drugs to treat serious and often life-threatening conditions. The company operates primarily in the healthcare and pharmaceutical markets. Affymax's primary clients include healthcare providers, hospitals, and clinics that require advanced medical treatments for their patients.

The business model of Affymax revolves around research and development (R&D) of new drugs, followed by clinical trials to ensure their safety and efficacy. Once a drug is approved by regulatory authorities, such as the FDA (Food and Drug Administration), Affymax then markets and sells these drugs to healthcare institutions. The company generates revenue through the sale of these pharmaceutical products.

Affymax's approach to making money is heavily reliant on the successful development and commercialization of its drug candidates. This involves significant investment in R&D, navigating regulatory approvals, and establishing partnerships with other pharmaceutical companies for distribution and marketing.

The company has faced legal challenges, as indicated by the ongoing shareholder derivative litigation. This type of litigation involves shareholders suing company executives on behalf of the company, usually for alleged breaches of fiduciary duty. Despite these challenges, Affymax continues to focus on its core mission of developing life-saving drugs.

In summary, Affymax, Inc. is a biopharmaceutical company dedicated to creating innovative treatments for serious health conditions, serving healthcare providers and institutions, and operating within the pharmaceutical market. The company makes money through the development, approval, and sale of its pharmaceutical products.

Keywords: biopharmaceutical, healthcare, pharmaceutical, R&D, clinical trials, FDA approval, drug development, revenue, litigation, innovation.